These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Safety and Effectiveness of Omnitrope®, a Biosimilar Recombinant Human Growth Hormone: More Than 10 Years' Experience from the PATRO Children Study. Pfäffle R, Bidlingmaier M, Kreitschmann-Andermahr I, Land C, Partsch CJ, Schwab KO, Sommer H, Backeljauw P, Kanumakala S, Loche S, Zouater H, Strasburger CJ. Horm Res Paediatr; 2020; 93(3):154-163. PubMed ID: 32814319 [Abstract] [Full Text] [Related]
10. Is the growth outcome of children with idiopathic short stature and isolated growth hormone deficiency following treatment with growth hormone and a luteinizing hormone-releasing hormone agonist superior to that obtained by GH alone? Colmenares A, González L, Gunczler P, Lanes R. J Pediatr Endocrinol Metab; 2012; 25(7-8):651-7. PubMed ID: 23155689 [Abstract] [Full Text] [Related]
18. Elevated insulin-like growth factor-I values in children with Prader-Willi syndrome compared with growth hormone (GH) deficiency children over two years of GH treatment. Feigerlová E, Diene G, Oliver I, Gennero I, Salles JP, Arnaud C, Tauber M. J Clin Endocrinol Metab; 2010 Oct; 95(10):4600-8. PubMed ID: 20926543 [Abstract] [Full Text] [Related]